Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings Inc (XERS) is a biopharmaceutical innovator developing ready-to-use therapies for complex conditions in endocrinology, neurology, and gastroenterology. This page aggregates official company announcements, regulatory milestones, and research developments for stakeholders tracking its progress.
Access timely updates on XERS' FDA-approved products including Gvoke (severe hypoglycemia), Recorlev (Cushing's Syndrome), and proprietary formulation platforms like XeriSol and XeriJect. Our curated news feed covers clinical trial results, partnership announcements, manufacturing updates, and financial disclosures essential for understanding the company's trajectory in advanced biotherapeutics.
This resource serves investors and healthcare professionals needing verified information about XERS' patient-centric solutions. Content is organized chronologically with clear sourcing to facilitate efficient research. Bookmark this page for structured access to earnings reports, regulatory filings, and scientific advancements from one of biopharma's most innovative formulation specialists.
Xeris Pharmaceuticals has announced a definitive agreement to acquire Strongbridge Biopharma for approximately $267 million, including stock and contingent value rights (CVRs). The transaction values Strongbridge at about $2.72 per share, reflecting a 12.9% premium based on its closing price on May 21, 2021. The deal, unanimously approved by both companies' boards, is expected to close in early Q4 2021. This merger will create Xeris Biopharma Holdings, combining their product portfolios and commercial infrastructures to enhance revenue growth and operational efficiencies in the specialty and rare disease markets.
Xeris Pharmaceuticals, Inc. (XERS) reported its first quarter 2021 results, highlighting strong financial performance despite pandemic challenges. Gvoke prescriptions exceeded 16,000, marking over 400% growth year-over-year. The company received EU approval for Ogluo and is targeting a Q4 2021 launch. Financially, Gvoke net sales reached $8.1 million, with a net loss of $18.4 million, improved from $29.2 million in the same quarter last year. As of March 31, 2021, Xeris held $135.9 million in cash and equivalents. Management is optimistic about market stability and product development.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced that CEO Paul R. Edick will participate in several virtual events, including:
- The diaTribe Foundation Musings event on May 13, 2021
- RBC Capital Markets Global Healthcare Conference on May 19, 2021
- Jefferies Global Healthcare Conference on June 2, 2021
The presentations are accessible via the Company's website. Xeris focuses on innovative injectable drug formulations and has developed technologies that enhance the ease of use for patients and caregivers, including its Gvoke® product in the U.S.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) will announce its Q1 2021 financial results before the U.S. market opens on May 13, 2021. A conference call will follow at 8:30 a.m. ET for management to discuss the financial and operational outcomes. Xeris is focused on developing innovative, ready-to-use injectable and infusible therapies, leveraging proprietary technologies like XeriSol™ and XeriJect™ to simplify drug administration. The company aims to improve patient experiences while reducing healthcare costs.
Xeris Pharmaceuticals (Nasdaq: XERS) announced an amendment to its loan agreement with Oxford Finance and Silicon Valley Bank, extending interest-only payments for up to 12 months. This allows the company to defer principal payments of $17.4 million initially due between January and December 2022 to January 2023. The final maturity date of the debt facility is set for June 1, 2024. CEO Paul R. Edick emphasized the flexibility this provides to conserve cash while advancing Gvoke's sales, which treats hypoglycemia.
Xeris Pharmaceuticals (Nasdaq: XERS) has received approval from the UK’s Medicines and Healthcare Regulatory Agency for Ogluo® (glucagon) injection, indicated for treating severe hypoglycemia in patients aged 2 and above with diabetes. Previously, Ogluo was approved by the European Commission in February 2021. The marketing authorization is recognized in the UK and 27 EU countries. Xeris is actively seeking commercialization partners, aiming for a fourth quarter 2021 launch in select EU regions. Gvoke, a similar product, was FDA-approved in September 2019.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced the grant of 15,250 restricted stock units to 10 new employees on March 31, 2021. This action was made under Xeris' Inducement Equity Plan, which incentivizes new hires with equity awards. The stock options will vest over four years, with specific vesting schedules tied to continued employment. Xeris specializes in ready-to-use injectable and infusible drug formulations, aimed at improving patient and healthcare experiences.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced a registered direct offering of 6,553,398 shares at $4.12 each, securing gross proceeds of $27 million. The offering, managed without underwriters, is expected to close on March 15, 2021. Proceeds will fund working capital and general corporate purposes, detailed in a forthcoming prospectus supplement. This offering is part of a shelf registration declared effective in August 2019 by the SEC. Xeris focuses on creating ready-to-use injectable therapies leveraging advanced formulation technologies.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) reported its fourth quarter and full-year 2020 financial results, highlighting continuous growth in Gvoke prescriptions, up 11% quarter-over-quarter and 350% year-over-year. The company secured a positive opinion from the EMA for Ogluo, with expectations for a Q4 2021 launch in select EU countries. Xeris also converted $39.1 million of convertible notes into shares, improving its cash position to $133.8 million. However, the net loss for Q4 2020 was $21.9 million, a decrease from $33.1 million in Q4 2019.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) will release its fourth quarter and full-year 2020 financial results on March 9, 2021, before U.S. markets open. A conference call is scheduled for 8:30 a.m. ET that same day to discuss the results. Xeris specializes in developing ready-to-use injectable and infusible drug formulations, leveraging its proprietary XeriSol™ and XeriJect™ technologies. These innovations aim to simplify medication administration, enhance stability, and reduce costs. For more information, visit www.xerispharma.com.
